

Transdermal Drug Delivery Technologies, Companies & Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2021

A Jain PharmaBiotech Report

A B O U T T H E A U T H O R

Professor K. K. Jain is a neurologist/neurosurgeon with specialist qualifications including Fellowships of the Royal Colleges of Surgeons in Australia and Canada. He has trained, practiced, and held academic positions in several countries including Switzerland, India, Iran, Germany, Canada, and USA. After retirement from neurosurgery, Prof. Jain remains a consultant in neurology. He is also working in the biotechnology/biopharmaceuticals industry and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is the CEO of Jain PharmaBiotech.

Prof. Jain's 492 publications include 35 books (6 as editor + 29 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. Books relevant to biotechnology and pharmaceuticals include "Role of Nanobiotechnology in Molecular Diagnostics" (2006), "Handbook of Nanomedicine" (Humana/Springer 2008; Chinese edition, Peking University Press 2011, 2nd ed Springer 2012, 3rd ed 2017), "Textbook of Personalized Medicine (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015, 3rd ed 2021), "Handbook of Biomarkers" (Springer 2010; Chinese edition by Chemical Industry Press 2016, 2nd edition Springer 2017), "Handbook of Neuroprotection" (Springer 2011, 2nd ed 2019), "Drug-induced Neurological Disorders", 4th ed, Springer 2021), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has edited "Drug Delivery to the Central Nervous System" (Humana/Springer 2010), "Drug Delivery Systems", 3rd edn (Springer 2019) and "Applied Neurogenomics" (Springer 2015). He has also written a "Textbook of Gene Therapy", which was the first book on this subject to be translated into the Chinese language. A book on gene therapy companies was published in 2000 by John Wiley & Sons. Updated material from both these books have been included in 2021 edition of a special report on Gene Therapy published by Jain PharmaBiotech Publications. Currently, he is writing "The Handbook of Alzheimer Disease" to be published by Springer in 2022.

A B O U T T H I S R E P O R T

The original report on Transdermal Drug Delivery appeared as a section in the author's Drug Delivery Systems published by Decision Resources Inc in 1998. The second edition was published by Informa Pharmaceuticals after detaching Cancer Drug Delivery and Central Nervous System Drug Delivery as separate reports in 2000. In 2002, Transdermal Drug Delivery was also detached, expanded, and updated to be issued as separate publications by Jain PharmaBiotech. The report was regularly updated since 2002, enlarged and rewritten for 2021 edition.

November 2021 (first published in 2002)
Copyright © 2021 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: <http://pharmabiotech.ch/>

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

T A B L E O F C O N T E N T S

0. Executive Summary	10
1. Basics of Transdermal Drug Delivery	12
Introduction	12
Historical landmarks in transdermal drug delivery	12
Anatomy and physiology of skin	13
Skin metabolomics and transcutaneous passage of drugs.....	13
Transcutaneous absorption	14
Transdermal versus other methods of drug delivery.....	14
Advantages of transdermal drug delivery	14
<i>First-Pass Effect.</i>	15
Drawbacks of transdermal delivery.....	15
Factors that influence transdermal drug delivery	15
Rate of permeation across the skin	16
Properties of the skin	16
Properties of drugs.....	17
<i>The role of pH and pharmacokinetics</i>	18
<i>Intradermal disposition of drugs after topical application.....</i>	18
Role of nanobiotechnology in understanding basis of transdermal delivery	18
2. Transdermal Drug Delivery Technologies	20
Introduction	20
Local application formulations.....	21
Crystalline topical formulations.....	21
Microemulsions for transdermal drug delivery.....	21
Nanoemulsions for transdermal drug delivery	22
Transdermal gel technology	23
Biphasix system.....	24
Penetration enhancers.....	24
Chemical enhancers	25
<i>Nitric oxide-based transdermal drug delivery.....</i>	27
Ionic liquids for transdermal delivery of drugs against bacterial biofilms on skin	27
Vesicular transdermal carriers	27
<i>Ethosomes</i>	27
<i>Elastic vesicles for transdermal drug delivery</i>	28
<i>Liposomes.....</i>	28
<i>Nanovesicles for transdermal drug delivery</i>	29
<i>Transfersomes.....</i>	29
Transdermal patches	31
Adhesives for transdermal patches	32
Commercial development of transdermal patches	33
Innovations in transdermal patches.....	33
<i>e-Patch™ controlled release micropump system.....</i>	34
<i>Patchless Transdermal Delivery System</i>	34
<i>Metered-dose transdermal system</i>	35
Polymers for transdermal drug delivery.....	35
Polymer membranes in transdermal patches	36
Film forming polymeric solutions.....	36
Crystal Reservoir System of Nitto Denko	37
Use of physical modalities to facilitate transdermal transport	37
Transdermal electrotransport	37
Electroporation	38
<i>Drug delivery by electroporation</i>	39
Cryoelectrophoresis	40
Iontophoresis	40
<i>Iontophoresis compared with electrophoresis</i>	41
<i>Application of iontophoresis for drug delivery</i>	41
<i>Patents in iontophoresis.....</i>	43
<i>Companies with technologies for drug delivery by iontophoresis</i>	43
Combination of electrophoresis and iontophoresis	44
<i>Dermaportation</i>	44
Radiofrequency-driven transdermal delivery	44
Microporation	45
Transcutaneous drug delivery by electropulsation	45
Companies involved in electroporation-based drug delivery	46
Electrode Scanning System	46
Use of electrostatic force in skin patch technology.....	46

Multiple Absorption Kinetic System.....	47
Transdermal drug delivery facilitated by heat	47
<i>Thermosensitive gels</i>	47
<i>Controlled, heat-aided drug delivery</i>	47
Ultrasound	48
Magnetophoresis.....	49
Use of lasers for transdermal drug delivery	50
<i>Laser-induced microporation</i>	50
<i>Transdermal drug delivery by laser-induced pressure waves</i>	50
<i>Transdermal drug delivery by laser-assisted changes in skin</i>	51
Transdermal delivery by gas under pressure	51
<i>Transdermal delivery with PowderJect gas gun</i>	51
<i>Microneedle assisted microparticle delivery by a gene gun</i>	52
<i>Microscission induced by gas</i>	52
Role of microelectronics in transdermal drug delivery	53
Microneedles and dermal microinjection technologies	53
Applications of microneedles	54
AdminPatch® microneedle array.....	55
Biodegradable microneedles	55
Ceramic microneedle arrays	56
Dissolvable microneedle patches.....	57
MicorCor	57
Microneedle arrays for drug delivery.....	58
Microneedle patch	59
MicroPyramid™ microneedles	60
Microstructured Transdermal Systems	60
Microneedle Array Patch technology	61
<i>Patenting of microneedle transdermal drug delivery</i>	61
<i>Microneedle safety</i>	61
Microneedle transdermal chip	62
Microneedle applicator device	62
Dissolving microneedles	62
Nanoject™ microneedle technology	63
Nanoneedle patch	64
PatchPump.....	64
Phase transition nanoneedle.....	64
Polymer microneedles	65
Silk microneedles.....	65
Vaccination for COVID-19 by microneedles.....	66
Tattooing for drug delivery	66
ZP Patch microprojections technology.....	66
Companies developing microneedles for transdermal drug delivery	67
Needlefree injections	68
Glide SDI® solid dose injector	68
Jet injection	68
Mini-Ject needlefree delivery system	68
MicroJet for painless injections	69
Nanoliter-volume pulsed microjets	69
SUMAVEL™ DosePro™ needle-less injection	69
Skin ablation or abrasion for drug delivery	70
Nanotechnology-based transdermal drug delivery	70
Delivery of nanostructured drugs from transdermal patches	70
Effect of mechanical flexion on penetration of bucky balls through the skin	70
Nanobiotechnology for transdermal application	71
<i>Nanoparticles and nanoemulsions for skin disorders</i>	71
<i>Nanogels</i>	71
<i>Nanopatches</i>	72
<i>Hyaluronic acid for facilitating transdermal passage of nanoconstructs</i>	72
<i>Ionic nanoparticle technology</i>	72
<i>SLN gel for treatment of skin disorders</i>	73
<i>Topical delivery of siRNA- nanoparticle conjugates</i>	73
<i>Transdermal nanoparticle preparations for systemic effect</i>	73
<i>Transdermal administration of nanocarriers</i>	74
Nanotechnology-based transdermal vaccination and immunotherapy	74
Safety issues of applications of nanomaterial carriers on the skin.....	75
Comparison of transdermal drug delivery systems	75
Transdermal drug design	76
In vitro testing of transdermal drug delivery systems	76
<i>Commercially available skin models for transdermal drug testing</i>	77
<i>FDA guidelines for post-approval changes in semisolid topical drugs</i>	77
In vivo testing of drug delivery systems	77

Infrared spectroscopy for evaluation of transdermal drug delivery.....	78
Methods for assessment of the performance of topically applied drugs.....	78
Modeling of transport through the skin.....	78
Concluding remarks on transdermal drug delivery technologies.....	79
Future developments in transdermal drug delivery	79
3. Transdermal Therapeutics	82
Introduction	82
Drugs that can be administered transdermally	82
Approved transdermal products	82
Drugs in clinical trials	84
Skin disorders.....	85
Cutaneous leishmaniasis	85
Hair loss	85
Iontophoretic drug delivery for nail disorders.....	86
Psoriasis	86
<i>Nanoemulsions for paclitaxel delivery in psoriasis.....</i>	86
Cardiovascular disorders	86
Transdermal estrogen for prevention of atherosclerotic cardiovascular disease	86
Transdermal drug delivery for angina pectoris	87
Transdermal drug delivery for hypertension	88
<i>Transdermal clonidine</i>	89
<i>Transdermal delivery of β-blockers for hypertension.....</i>	89
<i>Transdermal delivery of calcium channel blockers for hypertension</i>	89
Transdermal drug delivery for congestive heart failure.....	90
Transdermal beta blockers	90
Transdermal anticoagulants	91
Respiratory diseases.....	91
Asthma.....	91
Chronic obstructive pulmonary disease	92
Neurological and psychiatric disorders	92
Parkinson's disease	92
<i>Transdermal drug delivery for Parkinson's disease</i>	93
<i>Transdermal levodopa delivery systems.....</i>	93
<i>Transdermal dopamine agonists for Parkinson's disease.....</i>	93
<i>Rotigotine for Parkinson disease</i>	95
<i>Rotigotine for restless legs syndrome</i>	96
<i>Transdermal administration of other drugs for Parkinson disease</i>	97
Depression.....	97
<i>Antidepressants</i>	97
<i>Selective serotonin-reuptake inhibitors</i>	97
<i>Transdermal fluoxetine</i>	98
<i>Monoamine oxidase inhibitors.....</i>	98
<i>Transdermal selegiline</i>	99
<i>Trazodone hydrochloride.....</i>	100
<i>Venlafaxine</i>	100
<i>Bupropion</i>	100
Bipolar disorder	101
<i>Transdermal lithium</i>	101
Schizophrenia.....	101
<i>Transdermal haloperidol</i>	101
<i>Transdermal risperidone for treatment of schizophrenia</i>	102
<i>Transdermal blonanserin for treatment of schizophrenia</i>	102
Restless legs syndrome	102
Alzheimer's disease.....	103
<i>Transdermal rivastigmine.....</i>	103
<i>Transdermal donepezil.....</i>	103
<i>Transdermal galantamine.....</i>	104
<i>Transdermal arecoline</i>	104
Transdermal nicotine for Tourette syndrome	105
Attention deficit hyperactivity disorder.....	105
<i>Transdermal methylphenidate</i>	105
Migraine	106
<i>Transdermal sumatriptan</i>	106
<i>Transdermal zolmitriptan</i>	107
<i>Transdermal dihydroergotamine</i>	107
Epilepsy	108
Tinnitus/Vertigo	108
Transdermal nitroglycerin for vasospasm due to subarachnoid hemorrhage.....	108
Musculoskeletal disorders.....	109
Osteoporosis	109

<i>Transdermal alendronate</i>	109
<i>Transdermal estrogen</i>	109
<i>Transdermal human parathyroid hormone</i>	109
Osteoarthritis	110
Muscle spasticity	110
<i>Transdermal tizanidine</i>	111
Transdermal therapy of diabetes	111
Insulin delivery in diabetes by transdermal patches.....	111
Microneedle patch for glucose-responsive insulin delivery	111
Patch monitoring system for insulin delivery.....	112
Self-regulated patch for delivery of insulin and glucagon.....	113
Sonic Applicator & Control Device for TDD of insulin	113
V-Go® disposable insulin delivery device	113
ViaDor System for TDD of insulin	114
Companies developing devices for transdermal insulin delivery.....	114
Transdermal therapy of oral antidiabetic agents.....	114
Male disorders	115
Erectile dysfunction	115
<i>Topical and transdermal preparation for erectile dysfunction</i>	116
Hypogonadism in the male.....	116
<i>Topical testosterone</i>	116
Benign prostatic hypertrophy.....	118
<i>Tamsulosin TDS</i>	118
Women's health	118
Female sexual arousal disorder.....	118
Menopause.....	119
<i>Hormone replacement therapy for menopause</i>	119
<i>Effect of transdermal estradiol on bone density.</i>	121
<i>Transdermal PTH for postmenopausal osteoporosis</i>	121
<i>Transdermal testosterone for low libido in postmenopausal women</i>	121
Breast disorders	122
Dysmenorrhea.....	122
Female infertility	122
Contraception	123
Female contraception	123
<i>Ortho Evra™</i>	123
<i>TWIRLA</i>	124
<i>BAY86-5016</i>	124
<i>Desogestrel</i>	124
Male contraception.....	124
<i>Transdermal progestin plus testosterone</i>	124
Cancer	125
Delivery of the photosensitizer drug δ-amino levulinic acid.....	125
Intradermal delivery of cancer vaccines by adenoviral vectors	125
Nanoemulsion-based delivery of caffeine for skin cancer	126
Topical interferon α2b for cervical cancer and precancerous lesions	126
Transcutaneous electroporation for delivery of anticancer drugs	126
Transdermal delivery of peptide cancer vaccines.....	127
Transdermal drug delivery for prostate cancer	127
<i>Transdermal nitroglycerine for prostate cancer</i>	127
<i>Transdermal estradiol gel for prostate cancer</i>	127
<i>Transdermal leuprolide acetate for prostate cancer</i>	127
Transdermal drug delivery for breast cancer.....	128
<i>Afimoxifene topical gel for breast cancer</i>	128
Pain	128
Relief of pain associated with minor medical procedures	128
Transdermal lidocaine relief of postherpetic neuralgia	128
<i>Lidoderm®</i>	129
<i>Lidopat®</i>	129
<i>ZTlido</i>	129
Transdermal capsaicin for relief of pain	129
Nonsteroidal antiinflammatory drugs	129
<i>Topical NSAIDs</i>	129
<i>Transdermal ketoprofen</i>	130
<i>Topical opioids</i>	131
Cancer pain.....	132
<i>Transdermal fentanyl</i>	132
<i>Transdermal nitroglycerine as an adjuvant to opioids</i>	133
<i>Transdermal buprenorphine</i>	133
Chronic pain of non-malignant origin	133
Transdermal local anesthetics.....	134

Postoperative pain	134
<i>Transdermal fentanyl for the management of postoperative pain</i>	<i>134</i>
<i>Fibromyalgia</i>	<i>134</i>
Nanotechnology-based approved transdermal analgesic preparations	134
Nausea and vomiting	135
Motion sickness	135
Postoperative vomiting	135
Chemotherapy-induced nausea and vomiting	135
Antiaging strategies	135
Smoking cessation	136
Transdermal nicotine replacement.....	136
Use of nicotine patch for smoking cessation in pregnancy	137
Other methods of nicotine replacement	137
Other treatments for smoking cessation.....	137
Miscellaneous uses of transdermal drug delivery.....	138
Allergic rhinitis.....	138
Chronic fatigue syndrome	138
Delivery of cannabinoids	139
Overactive bladder and urinary incontinence	140
<i>Transdermal oxybutynin</i>	<i>140</i>
Viral infections.....	141
<i>Transdermal nanoparticles for immune enhancement in HIV.....</i>	<i>141</i>
<i>Transdermal IQP-0410 for HIV/AIDS</i>	<i>142</i>
Wound healing and ulcers	142
Transdermal gene therapy.....	142
Transdermal delivery of plasmid DNA by electroporation	143
Transdermal gene therapy for drug addiction	143
Transdermal antisense therapy	143
Transdermal vaccination.....	144
The skin as an immune organ.....	144
Technologies for transdermal vaccination	145
<i>Dissolvable microneedle array for vaccine delivery</i>	<i>145</i>
<i>Electroporation for administering DNA vaccines</i>	<i>145</i>
<i>High-density microarray patch for influenza vaccine</i>	<i>146</i>
<i>Microneedles for transdermal delivery of vaccines</i>	<i>147</i>
<i>Needle-free delivery of vaccines.....</i>	<i>148</i>
<i>Transcutaneous immunotherapy using nanodispersions</i>	<i>149</i>
Applications of transdermal vaccination	149
<i>HIV/AIDS vaccination by topical application.....</i>	<i>149</i>
<i>Transdermal DNA influenza vaccine.....</i>	<i>150</i>
<i>Transdermal Aβ vaccination for Alzheimer's disease</i>	<i>150</i>
<i>Transdermal vaccination for traveller's diarrhoea</i>	<i>150</i>
Epicutaneous desensitization for food allergy.....	151
Peanut patch for peanut allergy	153
Transdermal nutraceuticals	153
Complications of transdermal therapy	153
Adverse effects of drugs	153
Overdose effect	154
Skin complications	154
<i>MRI-induced skin burns from transdermal patches</i>	<i>154</i>
4. Markets for Transdermal Drug Delivery	156
Introduction	156
Global markets for drug delivery	156
Geographical distribution of transdermal drug delivery markets	157
Emerging transdermal drug delivery markets in Asia	157
Transdermal technology markets in therapeutic areas	157
Angina pectoris.....	158
Attention deficit hyperactivity disorder.....	158
Erectile dysfunction	159
Hypertension	159
Osteoporosis	159
Pain therapeutics	159
Parkinson's disease	159
Smoking cessation	160
Transdermal hormone replacement therapy for menopause	160
Transdermal testosterone replacement therapy for hypogonadism in the male	160
Transdermal contraceptive market	160
Markets according to transdermal technologies.....	161
Markets for microneedle-based transdermal drug delivery.....	161
Marketing strategies for transdermal drug delivery.....	161

Marketing advantages of transdermal drug delivery.....	162
Unmet needs in transdermal drug delivery	162
Regulatory aspects that affect transdermal drug delivery markets.....	163
Future prospects of transdermal drug delivery	164
Growth of new technologies used in transdermal drug delivery	164
Prospects of transdermal delivery for drugs coming off patents.....	164
Transdermal delivery of biologicals.....	165
Transdermal delivery of cosmetics	165
5. Companies involved in transdermal drug delivery	166
Profiles of companies.....	166
Top companies in transdermal drug delivery.....	166
Collaborations.....	286
6. References.....	290

Tables

Table 1-1: Historical landmarks in the development of transdermal drug delivery	12
Table 1-2: Transdermal vs oral and intravenous drug delivery	14
Table 1-3: Size ranges of molecules that can be delivered by transdermal route.....	17
Table 2-1: Technologies for transdermal drug delivery	20
Table 2-2: Chemical enhancers of skin penetration	25
Table 2-3: Drug-in-adhesive versus reservoir type of transdermal patch.....	31
Table 2-4: Companies with transdermal patches for drug delivery.....	33
Table 2-5: Companies with technologies for drug delivery by iontophoresis.....	43
Table 2-6: Companies involved in electroporation-based drug delivery	46
Table 2-7: Companies developing microneedles for transdermal drug delivery.....	67
Table 2-8: Comparison of transdermal drug delivery systems.....	75
Table 3-1: Approved transdermal products	82
Table 3-2: Transdermal drugs in clinical trials or approval process	84
Table 3-3: Companies developing devices for transdermal insulin delivery	114
Table 3-4: Selected transdermal systems GLP-1 antidiabetic agents.....	115
Table 4-1: Worldwide drug delivery market growth 2020 to 2030	156
Table 4-2: Transdermal drug delivery markets for geographical regions 2020 to 2030.....	157
Table 4-3: Markets for transdermal products for therapeutic areas 2020-2030	158
Table 4-4: Markets according to transdermal technologies 2020-2030.....	161
Table 4-5: Marketing strategies based on transdermal drug delivery technologies.....	161
Table 5-1: Top five companies in transdermal drug delivery	166
Table 5-2: Collaborations in transdermal drug delivery	286

Figures

Figure 1-1: Basic structure of the skin	13
Figure 1-2: Passages of transcutaneous drug absorption	14
Figure 1-3: Events governing transcutaneous drug absorption	16
Figure 2-1: Basic structure and function of transdermal drug delivery systems.....	31
Figure 2-2: Transdermal system for delivery of liquid drugs	32
Figure 2-3: Crystal Reservoir System of Nitto Denko	37
Figure 2-4: A schematic view of electroporation.....	38
Figure 2-5: Depiction of breakdown of the stratum corneum during electroporation	40
Figure 2-6: A schematic drawing of Iontophoresis.....	41
Figure 2-7: SonoPrep ultrasonic skin permeation	49
Figure 2-8: A a schematic sketch of PowderJect gas gun.....	52
Figure 2-9: Drug delivery using different types of microneedles (MN)	54
Figure 2-10: A schematic drawing of the microneedle patch.....	60
Figure 2-11: Preparation of solid-in-oil nanodispersion for transdermal application.....	71
Figure 3-1: Oral versus transdermal administration of a drug in Parkinson's disease	95
Figure 3-2: Control functions and user interface of insulin patch monitoring system.....	113
Figure 3-3: Transcutaneous immunotherapy using nanodispersions	149
Figure 3-4: Mechanism of action of epicutaneous immunotherapy.....	152
Figure 4-1: Unmet needs in transdermal drug delivery	163